In a follow-up to an outstanding overview of NSBB therapy in liver disease, Part 2 of this series by Anahita Rabiee presents evidence in support of earlier use of NSBBs in cirrhosis. Read on!
Anahita Rabiee
In the first post from new LFN author Anahita Rabiee, we are gifted an authoritative review on the Whys and Hows of beta-blockade in decompensated cirrhosis! You definitely want to read this one!
Can beta-blockade in patients with clinically significant portal hypertension prevent decompensations? The PREDESCI trial sought out to determine just that!
Lizzie Aby
In part 2 of our coagulopathy series, we take a deeper dive and learn the ways in which end-stage liver disease alters the body's normal hemostatic mechanisms.
Hersh Shroff
A 60-year-old male with a history of HBV exposure, HCV with spontaneous clearance, and myelofibrosis with transfusion-dependent pancytopenia presents with tense ascites and coffee ground emesis. On...
Sarang Thaker
Patients with end-stage liver disease have elevated INRs. They bleed frequently and they clot perhaps more frequently. Do they need FFP before a paracentesis? What's a TEG? These questions answered...
In Part 1 of this series, we reviewed what came BEFORE the MELD score—Child-Turcotte-Pugh classification. We additionally discussed the history behind MELD, what is included in its calculation and why...
Alyson Kaplan
The Model for End-stage Liver Disease (or MELD) score is used to determine patient priority for liver transplantation. But have you ever wondered why? Let us review the history and the literature to...
A review of the study on rifaximin as an adjunctive therapy in treatment of hepatic encephalopathy.
Can polyethylene glycol (PEG) be used to treat hepatic encephalopathy in hospitalized patients?
Alex Vogel
Enter your email here and receive monthly newsletters with new LFN material.
Registration failed. Please try again later.